Molecular mechanisms and clinical application of multipotent stem cells for spinal cord injury

M Szymoniuk, J Litak, L Sakwa, A Dryla, W Zezuliński… - Cells, 2022 - mdpi.com
Spinal Cord Injury (SCI) is a common neurological disorder with devastating psychical and
psychosocial sequelae. The majority of patients after SCI suffer from permanent disability …

Diagnosis and management of neuropathic pain in spine diseases

J Bielewicz, M Kamieniak, M Szymoniuk, J Litak… - Journal of Clinical …, 2023 - mdpi.com
Neuropathic pain is generally defined as a non-physiological pain experience caused by
damage to the nervous system. It can occur spontaneously, as a reaction to a given stimulus …

Anti-inflammatory-antioxidant modifications and synbiotics improved health-related conditions in patients with progressive forms of multiple sclerosis: A single-center …

AR Moravejolahkami, A Chitsaz… - … Therapies in Clinical …, 2023 - Elsevier
Background and purpose There is growing evidence that dietary modification can improve
clinical manifestations in multiple sclerosis (MS) patients. This study aimed to assess the …

[HTML][HTML] High throughput drug screening identifies resveratrol as suppressor of hepatic SELENOP expression

J Hackler, K Demircan, TS Chillon, Q Sun, N Geisler… - Redox Biology, 2023 - Elsevier
Abstract Introduction Selenium (Se) is an essential trace element that exerts its effects
mainly as the proteinogenic amino acid selenocysteine within a small set of selenoproteins …

Multiple Sclerosis and Other Acquired Demyelinating Diseases of the Central Nervous System

MD Kornberg, PA Calabresi - Cold Spring Harbor …, 2024 - cshperspectives.cshlp.org
Acquired demyelinating diseases of the central nervous system (CNS) comprise
inflammatory conditions, including multiple sclerosis (MS) and related diseases, as well as …

Treatment with MDL 72527 ameliorated clinical symptoms, retinal ganglion cell loss, optic nerve inflammation, and improved visual acuity in an experimental model of …

F Liu, M Alfarhan, L Baker, N Shenoy, Y Liao… - Cells, 2022 - mdpi.com
Multiple Sclerosis (MS) is a highly disabling neurological disease characterized by
inflammation, neuronal damage, and demyelination. Vision impairment is one of the major …

Treatment algorithms of relapsing multiple sclerosis: an exploration based on the available disease-modifying therapies in China

J Guo, J Wu, L Wang, H Liu, X Wu… - Therapeutic …, 2024 - journals.sagepub.com
Multiple sclerosis (MS) was defined as a rare disease in China due to its low prevalence. For
a long time, interferon β was the only approved disease-modifying therapy (DMT). Since the …

Anti-inflammatory action of new hybrid N-acyl-[1,2]dithiolo-[3,4-c]quinoline-1-thione

SM Medvedeva, A Petrou, M Fesatidou… - SAR and QSAR in …, 2024 - Taylor & Francis
Most of pharmaceutical agents display a number of biological activities. It is obvious that
testing even one compound for thousands of biological activities is not practically possible. A …

Bruton's Tyrosine Kinase Inhibitors for Multiple Sclerosis Treatment: A New Frontier

BM Greenberg - Neurologic Clinics, 2024 - neurologic.theclinics.com
Multiple sclerosis (MS) has had a revolution in therapeutics during the last 30 years. Since
the Federal Drug Administration (FDA) approval of interferon beta 1b in 1993, more than 20 …

A novel PROTAC molecule dBET1 alleviates pathogenesis of experimental autoimmune encephalomyelitis in mice by degrading BRD4

Z Song, J Li, Y He, X Wang, J Tian, Y Wu - International …, 2024 - Elsevier
Neuroinflammation and neurodegeneration are hallmarks of multiple sclerosis (MS).
Bromodomain-containing protein 4 (BRD4), a bromodomain and extra-terminal domain …